Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

Ip, MD, discusses the available treatments for nonproliferative diabetic retinopathy. Ip said about 50% of responders to an American Society of Retina Specialists survey reported that they were ...

HealthDay News — Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase 4 inhibitor (DPP4i), according ...

The collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...

Diabetic retinopathy is a serious concern for people dealing with diabetes. Detecting diabetic retinopathy poses significant challenges, requiring skilled professionals, extensive manual image ...

Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company’s strategic outlook for ...

Diabetic retinopathy (DR) remains the leading cause of vision loss and blindness in people of working age, in spite of the fact that current treatments are effective. Vision loss occurs in DR due ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...